Solventum Corporation $SOLV Shares Acquired by CIBC Asset Management Inc

CIBC Asset Management Inc grew its stake in shares of Solventum Corporation (NYSE:SOLV) by 102.2% in the 4th quarter, Holdings Channel.com reports. The fund owned 35,603 shares of the company’s stock after purchasing an additional 17,991 shares during the quarter. CIBC Asset Management Inc’s holdings in Solventum were worth $2,821,000 as of its most recent SEC filing.

Several other hedge funds also recently added to or reduced their stakes in SOLV. Hilltop National Bank grew its holdings in Solventum by 71.3% during the 4th quarter. Hilltop National Bank now owns 310 shares of the company’s stock worth $25,000 after acquiring an additional 129 shares in the last quarter. Measured Wealth Private Client Group LLC acquired a new position in Solventum during the 3rd quarter worth $25,000. JNBA Financial Advisors grew its holdings in Solventum by 205.4% during the 4th quarter. JNBA Financial Advisors now owns 339 shares of the company’s stock worth $27,000 after acquiring an additional 228 shares in the last quarter. CYBER HORNET ETFs LLC acquired a new position in Solventum during the 2nd quarter worth $28,000. Finally, City State Bank grew its holdings in Solventum by 166.7% during the 4th quarter. City State Bank now owns 384 shares of the company’s stock worth $30,000 after acquiring an additional 240 shares in the last quarter.

Analysts Set New Price Targets

Several research analysts have weighed in on the stock. Stifel Nicolaus decreased their price objective on shares of Solventum from $105.00 to $90.00 and set a “buy” rating for the company in a report on Wednesday, May 6th. KeyCorp raised their price objective on shares of Solventum from $92.00 to $93.00 and gave the stock an “overweight” rating in a report on Wednesday, May 6th. Rothschild & Co Redburn assumed coverage on shares of Solventum in a report on Tuesday, March 24th. They set a “sell” rating and a $60.00 price objective for the company. BTIG Research reissued a “buy” rating and set a $89.00 price objective on shares of Solventum in a report on Wednesday, May 6th. Finally, Wells Fargo & Company decreased their price objective on shares of Solventum from $83.00 to $70.00 and set an “equal weight” rating for the company in a report on Wednesday, May 6th. Eight analysts have rated the stock with a Buy rating, five have issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $84.25.

Insider Activity at Solventum

In other Solventum news, Director Amy Mcbride Wendell purchased 1,475 shares of the firm’s stock in a transaction dated Tuesday, March 10th. The stock was acquired at an average cost of $68.03 per share, with a total value of $100,344.25. Following the acquisition, the director owned 5,039 shares of the company’s stock, valued at approximately $342,803.17. This represents a 41.39% increase in their position. The purchase was disclosed in a filing with the SEC, which is accessible through this link. Company insiders own 0.24% of the company’s stock.

Solventum Trading Up 0.1%

NYSE SOLV opened at $81.07 on Monday. Solventum Corporation has a one year low of $62.38 and a one year high of $88.20. The company has a 50-day simple moving average of $70.91 and a 200-day simple moving average of $75.20. The company has a debt-to-equity ratio of 0.96, a quick ratio of 0.75 and a current ratio of 1.07. The firm has a market capitalization of $14.04 billion, a PE ratio of 9.93, a price-to-earnings-growth ratio of 1.25 and a beta of 0.69.

Solventum (NYSE:SOLV) last posted its quarterly earnings results on Tuesday, May 5th. The company reported $1.48 EPS for the quarter, beating the consensus estimate of $1.35 by $0.13. Solventum had a net margin of 17.33% and a return on equity of 23.51%. The business had revenue of $2.01 billion during the quarter, compared to analyst estimates of $1.97 billion. During the same period in the previous year, the business posted $1.34 EPS. The company’s quarterly revenue was down 3.0% on a year-over-year basis. Solventum has set its FY 2026 guidance at 6.600-6.600 EPS. On average, equities analysts forecast that Solventum Corporation will post 6.58 earnings per share for the current year.

Solventum Company Profile

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration. The Medsurg segment is a provider of solutions including advanced wound care, I.V. site management, sterilization assurance, temperature management, surgical supplies, stethoscopes, and medical electrodes.